Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 175 companies set new 52-week highs.
Why Is Dicerna Stock Getting Slammed Today?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced top-line results from PHYOX2 pivotal trial of nedosiran, RNAi therapeutic, for primary hyperoxaluria (PH). The trial…
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 159 companies achieved new highs for the year.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Morgan Stanley Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $234
Morgan Stanley analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $224 to $234.
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $216
Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $196 to $216.
Piper Sandler Downgrades Alnylam Pharmaceuticals to Neutral, Announces $181 Price Target
Piper Sandler analyst Edward Tenthoff downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Overweight to Neutral and announces $181 price target.
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.